A. Karpe

发表

Distress Management in Patients With Head and Neck Cancer Before Start of Palliative Chemotherapy: A Practical Approach

J. Deodhar, K. Prabhash, S. Chakraborty, 2018, Journal of global oncology.

Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients

A. Bhattacharjee, K. Prabhash, V. Noronha, 2018, South Asian journal of cancer.

Technically unresectable recurrent oral cancers: Is NACT the answer?

A. Mahajan, S. Arya, P. Pai, 2016, Oral oncology.

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?

Rajiv Kumar, A. Mahajan, A. Bhattacharjee, 2017, Chemotherapy research and practice.

Expectations and preferences for palliative chemotherapy in head and neck cancers patients.

J. Deodhar, A. Bhattacharjee, K. Prabhash, 2016, Oral oncology.

Metronomic palliative chemotherapy in maxillary sinus tumor

K. Prabhash, V. Patil, A. Joshi, 2016, South Asian Journal of Cancer.

Drug-sensitive FGFR3 mutations in lung adenocarcinoma

A. Dutt, P. Upadhyay, A. Ingle, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy

Rajiv Kumar, A. Mahajan, A. Bhattacharjee, 2017, Ecancermedicalscience.

Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of a Phase III randomized trial to compare the benefit of gefitinib versus pemetrexed/carboplatin for epidermal growth factor receptor-mutated non-small cell lung cancer

A. Mahajan, A. Bhattacharjee, K. Prabhash, 2019, Cancer Research, Statistics, and Treatment.

Tyrosine Kinase Inhibitor versus Physician Choice Chemotherapy in Second-Line Epidermal Growth Factor Receptor Mutation Non-Small Cell Lung Cancer: Post hoc Analysis of Randomized Control Trial

Rajiv Kumar, A. Mahajan, A. Bhattacharjee, 2018, Indian Journal of Medical and Paediatric Oncology.

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma

Rajiv Kumar, A. Mahajan, A. Bhattacharjee, 2017, ESMO Open.

Chimerism in Hematopoietic Stem Cell Transplantation

A. Karpe, K. Patel, M. Parihar, 2021, Contemporary Bone Marrow Transplantation.

Outcomes in Treatment-Naïve Patients With Metastatic Extremity Osteosarcoma Treated With OGS-12, a Novel Non–High-Dose Methotrexate–Based, Dose-Dense Combination Chemotherapy, in a Tertiary Care Cancer Center

Sudeep Gupta, A. Chandrasekharan, A. Karpe, 2018, Journal of global oncology.

Efficacy of second-line erlotinib in patients postprogression of first-line chemotherapy in head and neck cancers.

A. Bhattacharjee, K. Prabhash, V. Noronha, 2015, Indian journal of cancer.

Towards a comprehensive head-and-neck oncological radiology (HNOR) consortium: Are we there yet?

T. Basu, A. Karpe, A. Mahuvakar, 2023, Cancer Research, Statistics, and Treatment.

Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?

Rajiv Kumar, A. Mahajan, A. Bhattacharjee, 2018, Lung India : official organ of Indian Chest Society.